Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
about
Devices in the management of advanced, chronic heart failureLeft ventricular assist devices as a bridge to cardiac transplantation.Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?Imaging left-ventricular mechanical activation in heart failure patients using cine DENSE MRI: Validation and implications for cardiac resynchronization therapy.Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008.Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure.EAARN score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on pre-implantation risk factors.Efficacy of implantable cardioconverter defibrillator or cardiac resynchronization therapy compared with combined therapy in survival of patients with heart failure: a meta-analysis.Current Evidence and Recommendations for Cardiac Resynchronisation Therapy.An Overview of Current Cardiac Resynchronization Therapy.Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysisEfficacy of cardiac resynchronization with defibrillator insertion in patients undergone coronary artery bypass graft: a cohort study of cardiac functionAssessment and management of the failing heart in children.New York Heart Association functional class predicts exercise parameters in the current era.Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan: Analysis of the Japan cardiac device treatment registry database.Decision making in advanced heart failure: a scientific statement from the American Heart AssociationUse of implantable cardioverter-defibrillators.The potential role of cardiac resynchronization therapy in acute heart failure syndromes.A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy.Long term effects of cardiac resynchronization therapy in non-ambulatory NYHA IV heart failure patients.Treatment options in end-stage heart failure: where to go from here?Traditional heart failure medications and sudden cardiac death prevention: a review.Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the better.Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy.CRT-D Therapy in Patients with Decompensated NYHA Class-Four CHFNew guidelines for cardiac resynchronisation therapy: simplicity or complexity for the doctor?The effectiveness of cardiac resynchronization therapy for patients with New York Heart Association class IV non-ambulatory heart failure.Electrical devices for left ventricular dysfunction and heart failure: do we need revised guidelines?Implantation of cardiac defibrillators for primary prevention: a pendulum too far?Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker.One-year outcome after CRT implantation in NYHA class IV in comparison to NYHA class III patients.Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure.National Institute for Health and Care Excellence 2014 guidance on cardiac implantable electronic devices: health economics reloaded.Cardiac resynchronisation therapy: pacemaker versus internal cardioverter-defibrillator in patients with impaired left ventricular function.2010 Focused Update of ESC Guidelines on device therapy in heart failure2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy De2010 Focused Update of ESC Guidelines on device therapy in heart failureValidation of Seattle Heart Failure Model for mortality risk prediction in patients treated with cardiac resynchronization therapy
P2860
Q24630052-F5931DDC-FE65-434B-96EF-21928E6304A4Q26999337-140323A4-DF0A-4C23-B8FE-986FE54455D2Q30235600-E2576288-B011-4F28-AA71-9CC47C6430DAQ30275043-6D50BBAD-2BF7-493B-AFA8-B788A800B131Q30813903-9CEC77B4-C545-4090-BEEB-6C59EBC89914Q33735354-5EE1D701-1055-4C92-9F60-23CD54893170Q35035181-D39CA6D3-A712-4037-B9A4-95E6CD6BCE2EQ36152171-246D0A7B-A942-49D6-BCFC-B25338E08637Q36458928-60ACEED0-E512-49C1-958B-F69D71E157D1Q36721967-C58A03AB-5E45-465B-BB80-FCDA06F0E775Q36936066-3A879440-3DE5-459A-8A0C-F327CF46B96EQ36987794-BC6BFFD5-75EE-4E17-9AA5-1681A8DE519DQ37354328-648962AB-E4C3-4CC3-AFB9-E9593E4BF5ECQ37389537-03719C32-1F8D-46A9-BAD9-E2015EDCBF3EQ37455101-D20A6EAC-F301-4EE9-81EF-524DC1DC9180Q37486284-1C046457-D06B-4067-9DEA-28A2BB4A76C2Q37818218-6100F796-F7F6-4A08-A8C5-5666C0BE70C3Q37856796-B069DD0A-589F-469A-82E7-B0A73E67BD21Q37904878-5A8EBC44-0CAD-4665-BC01-3713994CC2E5Q37931324-0F99C560-B6DC-417F-8086-976D9D75555EQ37956162-7EFE9024-D13C-4F91-93C0-0B64AF2E362EQ38114415-EC1CC701-6801-4DF5-B386-2720788C6547Q39136145-2DA5F6D3-E1CA-4D98-936E-EB0F22A72F6BQ39705886-5A140369-7A0E-4A9C-8C81-B56FF168753DQ41124653-3F375911-53A1-42BB-9B12-99615FF7C230Q42260520-E4D155DC-38E7-46E2-AB41-6305B09E5549Q42409952-5F8C2BD0-C2CD-49F3-AD9A-94C913F6BFC9Q43009514-26B15CCB-B468-40D1-8DDE-9F6521119454Q43773342-7EEF6021-55BF-46B0-947D-EE53E887F465Q45028246-12499902-9CBA-45E3-B290-B32A8D462451Q46920444-9F31EAA8-1F80-4E68-A9DA-A412E1CB060FQ48269482-AF47691A-C382-4EAF-B7C3-88AE24150BD3Q48883827-0FDD02D7-9BCB-4092-BB71-83C86D5E65EEQ50582675-81372A49-F19C-49BB-A929-BF00082725B0Q53584406-F8E03DDC-9DE1-4416-88F9-F695493418C1Q57312500-7E3820A7-3B36-48D1-AB9D-0FDEEDA74616Q57312501-BFFEB657-FA06-4443-85EC-C8402237CF37Q57312502-CD30D554-A5F2-4D58-A431-7850D9416303Q57786185-7AAAAB38-E2EA-4C83-8B6F-6178B971F3D5
P2860
Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effects of cardiac resynchroni ...... iation class IV heart failure.
@ast
Effects of cardiac resynchroni ...... iation class IV heart failure.
@en
Effects of cardiac resynchroni ...... iation class IV heart failure.
@nl
type
label
Effects of cardiac resynchroni ...... iation class IV heart failure.
@ast
Effects of cardiac resynchroni ...... iation class IV heart failure.
@en
Effects of cardiac resynchroni ...... iation class IV heart failure.
@nl
prefLabel
Effects of cardiac resynchroni ...... iation class IV heart failure.
@ast
Effects of cardiac resynchroni ...... iation class IV heart failure.
@en
Effects of cardiac resynchroni ...... iation class IV heart failure.
@nl
P2093
P921
P1433
P1476
Effects of cardiac resynchroni ...... iation class IV heart failure.
@en
P2093
Arthur M Feldman
Brian Jaski
David Mann
Elizabeth Galle
Fred Ecklund
Inder Anand
Jalal K Ghali
JoAnn Lindenfeld
John Boehmer
Jonathan S Steinberg
P304
P356
10.1161/CIRCULATIONAHA.106.629261
P407
P577
2006-12-26T00:00:00Z